Dermapharm Holding SE Sustainability Profile
Dermapharm Holding SE, headquartered in Germany, is a prominent player in the pharmaceutical industry, specialising in the development and production of high-quality generic and specialty pharmaceuticals. Founded in 1991, the company has established a strong presence across Europe, with significant operations in various key markets. The firm is renowned for its innovative approach to drug formulation, focusing on areas such as pain management, oncology, and central nervous system disorders. Dermapharm's commitment to quality and efficiency has positioned it as a trusted partner for healthcare providers and patients alike. With a robust portfolio of products, Dermapharm continues to achieve notable milestones, reinforcing its status as a leader in the pharmaceutical sector.
DitchCarbon Score
How does Dermapharm Holding SE's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Dermapharm Holding SE's score of 22 is lower than 80% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Dermapharm Holding SE's reported carbon emissions
Dermapharm Holding SE, headquartered in Germany, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. The company has not established documented reduction targets or climate pledges, which suggests a lack of formal commitments to reducing greenhouse gas emissions at this time. It is important to note that Dermapharm Holding SE is a current subsidiary, and any potential emissions data or climate initiatives may be cascaded from its parent organization. However, no specific information regarding such data or initiatives has been provided. In the context of the pharmaceutical industry, companies are increasingly expected to adopt robust climate strategies and transparency in emissions reporting. As of now, Dermapharm Holding SE appears to be in the early stages of addressing climate commitments, with no publicly available targets or achievements to report.
How Carbon Intensive is Dermapharm Holding SE's Industry?
How Carbon Intensive is Dermapharm Holding SE's Location?
Dermapharm Holding SE's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Dermapharm Holding SE has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
